Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Ferroptosis is a new form of regulated, non‐apoptotic cell death driven by iron‐dependent
phospholipid peroxidation. Its therapeutic potential is however, greatly limited by the low …

Autophagy-based protein degradation is emerging as a promising technology for anti-
diseases and innovative drug discovery. Here, we demonstrate a novel type of autophagy …

Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

The homologous cytokines macrophage migration inhibitory factor (MIF) and d-dopachrome
tautomerase (d-DT or MIF2) play key roles in cancers. Molecules binding to the MIF …

Recent years have witnessed the rapid development of targeted protein degradation (TPD),
especially proteolysis targeting chimeras. These degraders have manifested many …

Background As an inflammatory factor and oncogenic driver protein, the pleiotropic cytokine
macrophage migration inhibitory factor (MIF) plays a crucial role in the osteosarcoma …

Proteolysis-targeting chimeras (PROTACs) is a promising strategy for treatment of various
diseases by degrading of disease-related proteins in recent years. Up to now, most …